These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 36882326)

  • 1. Associations Between CSF Markers of Inflammation, White Matter Lesions, and Cognitive Decline in Individuals Without Dementia.
    Gertje EC; Janelidze S; van Westen D; Cullen N; Stomrud E; Palmqvist S; Hansson O; Mattsson-Carlgren N
    Neurology; 2023 Apr; 100(17):e1812-e1824. PubMed ID: 36882326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease.
    Janelidze S; Mattsson N; Stomrud E; Lindberg O; Palmqvist S; Zetterberg H; Blennow K; Hansson O
    Neurology; 2018 Aug; 91(9):e867-e877. PubMed ID: 30054439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers.
    Mattsson-Carlgren N; Salvadó G; Ashton NJ; Tideman P; Stomrud E; Zetterberg H; Ossenkoppele R; Betthauser TJ; Cody KA; Jonaitis EM; Langhough R; Palmqvist S; Blennow K; Janelidze S; Johnson SC; Hansson O
    JAMA Neurol; 2023 Apr; 80(4):360-369. PubMed ID: 36745413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
    Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
    JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations of CSF PDGFRβ With Aging, Blood-Brain Barrier Damage, Neuroinflammation, and Alzheimer Disease Pathologic Changes.
    Cicognola C; Mattsson-Carlgren N; van Westen D; Zetterberg H; Blennow K; Palmqvist S; Ahmadi K; Strandberg O; Stomrud E; Janelidze S; Hansson O
    Neurology; 2023 Jul; 101(1):e30-e39. PubMed ID: 37137722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigating White Matter Neuroinflammation in Alzheimer Disease Using Diffusion-Based Neuroinflammation Imaging.
    Wang Q; Schindler SE; Chen G; Mckay NS; McCullough A; Flores S; Liu J; Sun Z; Wang S; Wang W; Hassenstab J; Cruchaga C; Perrin RJ; Fagan AM; Morris JC; Wang Y; Benzinger TLS
    Neurology; 2024 Feb; 102(4):e208013. PubMed ID: 38315956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Enlarged Perivascular Spaces and Measures of Small Vessel and Alzheimer Disease.
    Gertje EC; van Westen D; Panizo C; Mattsson-Carlgren N; Hansson O
    Neurology; 2021 Jan; 96(2):e193-e202. PubMed ID: 33046608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals.
    Simrén J; Brum WS; Ashton NJ; Benedet AL; Karikari TK; Kvartsberg H; Sjons E; Lussier FZ; Chamoun M; Stevenson J; Hopewell R; Pallen V; Ye K; Pascoal TA; Zetterberg H; Rosa-Neto P; Blennow K
    Alzheimers Res Ther; 2022 Dec; 14(1):192. PubMed ID: 36544221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CSF placental growth factor - a novel candidate biomarker of frontotemporal dementia.
    Hansson O; Santillo AF; Meeter LH; Nilsson K; Landqvist Waldö M; Nilsson C; Blennow K; van Swieten JC; Janelidze S
    Ann Clin Transl Neurol; 2019 May; 6(5):863-872. PubMed ID: 31139684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults.
    Popp J; Oikonomidi A; Tautvydaitė D; Dayon L; Bacher M; Migliavacca E; Henry H; Kirkland R; Severin I; Wojcik J; Bowman GL
    Brain Behav Immun; 2017 May; 62():203-211. PubMed ID: 28161476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effects of Tau, Amyloid, and White Matter Lesions on Mobility, Dual Tasking, and Balance in Older People.
    Nilsson MH; Tangen GG; Palmqvist S; van Westen D; Mattsson-Carlgren N; Stomrud E; Hansson O
    J Gerontol A Biol Sci Med Sci; 2021 Mar; 76(4):683-691. PubMed ID: 32506119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of CSF GAP-43 With the Rate of Cognitive Decline and Progression to Dementia in Amyloid-Positive Individuals.
    Öhrfelt A; Benedet AL; Ashton NJ; Kvartsberg H; Vandijck M; Weiner MW; Trojanowski JQ; Shaw LM; Zetterberg H; Blennow K;
    Neurology; 2023 Jan; 100(3):e275-e285. PubMed ID: 36192174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid.
    Selnes P; Blennow K; Zetterberg H; Grambaite R; Rosengren L; Johnsen L; Stenset V; Fladby T
    Cerebrospinal Fluid Res; 2010 Jul; 7():10. PubMed ID: 20673341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of CSF Aβ
    Cullen N; Janelidze S; Palmqvist S; Stomrud E; Mattsson-Carlgren N; Hansson O;
    Neurology; 2022 Mar; 98(9):e958-e967. PubMed ID: 34937781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sex differences in Alzheimer's disease: plasma MMP-9 and markers of disease severity.
    Tsiknia AA; Sundermann EE; Reas ET; Edland SD; Brewer JB; Galasko D; Banks SJ;
    Alzheimers Res Ther; 2022 Nov; 14(1):160. PubMed ID: 36324151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. White matter hyperintensities and CSF Alzheimer disease biomarkers in preclinical Alzheimer disease.
    Soldan A; Pettigrew C; Zhu Y; Wang MC; Moghekar A; Gottesman RF; Singh B; Martinez O; Fletcher E; DeCarli C; Albert M;
    Neurology; 2020 Mar; 94(9):e950-e960. PubMed ID: 31888969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age, vascular disease, and Alzheimer's disease pathologies in amyloid negative elderly adults.
    Guo T; Landau SM; Jagust WJ;
    Alzheimers Res Ther; 2021 Oct; 13(1):174. PubMed ID: 34654465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic syndrome biomarkers relate to rate of cognitive decline in MCI and dementia stages of Alzheimer's disease.
    Pillai JA; Bena J; Bekris L; Kodur N; Kasumov T; Leverenz JB; Kashyap SR;
    Alzheimers Res Ther; 2023 Mar; 15(1):54. PubMed ID: 36927447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
    Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
    Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebral white matter lesions - associations with Aβ isoforms and amyloid PET.
    van Westen D; Lindqvist D; Blennow K; Minthon L; Nägga K; Stomrud E; Zetterberg H; Hansson O
    Sci Rep; 2016 Feb; 6():20709. PubMed ID: 26856756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.